Results 61 to 70 of about 25,325 (232)

TSC2 regulates PKM2 phosphorylation in an mTORC1-independent manner.

, 2020
(A) Immunoblot analysis of TSC2, phospho-PKM2 [Ser37], PKM2 and Phospho-S6 [Ser235/236] in 621–101 (TSC2-) and 621–103 (TSC2+) cells (n = 3); β-actin as a loading control. (B) Densitometry analysis of phospho-PKM2 [Ser37] was performed (n = 3).
Erik Zhang (70061), Aristotelis Astreinidis (8474073), Xiaolei Liu (104141), Eric P. Smith (2932587), Shuk-Mei Ho (128463), Yuet-Kin Leung (565316), Yiyang Lu (4502335), Chenggang Li (131849), Jane J. Yu (8474076), Elizabeth J. Kopras (8474070)   +9 more
core   +1 more source

Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.

PLoS ONE, 2021
Inactivating mutations in either TSC1 or TSC2 cause Tuberous Sclerosis Complex, an autosomal dominant disorder, characterized by multi-system tumor and hamartoma development.
Evelyn M Mrozek, Vineeta Bajaj, Yanan Guo, Izabela A Malinowska, Jianming Zhang, David J Kwiatkowski   +5 more
doaj   +1 more source

Developmental pathways to autism in tuberous sclerosis complex: Evidence from a longitudinal cohort

Epilepsia, EarlyView.
Abstract The association between autism spectrum disorder (hereafter referred to as autism) and tuberous sclerosis complex (TSC) is well established, yet the developmental pathways linking genetic mutation, cortical pathology, and epilepsy with autism remain unclear. The Tuberous Sclerosis 2000 Study recruited children newly diagnosed with TSC (N = 125)
Fiona S. McEwen, Abigail K. Runicles, Holan Liang, Emma Woodhouse, Lisa Underwood, Elizabeth Shephard, Edward D. Barker, Fintan Sheerin, Juul W. Steenbruggen, Tuberous Sclerosis 2000 Study Group, John R. W. Yates, Charlotte Tye, Patrick F. Bolton   +12 more
wiley   +1 more source

Comprehensive Genetic Analysis Results of TSC1/TSC2 Genes in Patients with Clinical Suspicion of Tuberous Sclerosis Complex and Definition of 3 Novel Variants

, 2021
Background: Tuberous Sclerosis Complex is an autosomal dominant multi-system disorder with an incidence of about 1 in 6000 live births. Defects in either TSC1 (* 605284) or TSC2 (* 191092) genes encoding the components of the Tuberous Sclerosis Complex ...
Selma Demir, Atli, Emine Ikbal, Karal, Yasemin, Engin Atlı, Eker, Damla, Yalcintepe, Sinem, Demir, Selma, Yalcin, Yelda, Emine İkbal Atlı, Damla Eker, Sinem Yalçıntepe, Yasemin Karal, Yelda Yalçın, Hakan Gürkan, Atli, Engin   +14 more
core   +1 more source

Hypomyelination following deletion of Tsc2 in oligodendrocyte precursors [PDF]

Annals of Clinical and Translational Neurology, 2015
AbstractObjectiveWhile abnormalities in myelin in tuberous sclerosis complex (TSC) have been known for some time, recent imaging‐based data suggest myelin abnormalities may be independent of the pathognomonic cortical lesions (“tubers”). Multiple mouse models of TSC exhibit myelination deficits, though the cell types responsible and the mechanisms ...
Carson, Robert P., Kelm, Nathaniel D., West, Kathryn L., Does, Mark D., Fu, Cary, Weaver, Grace, McBrier, Eleanor, Parker, Brittany, Grier, Mark D., Ess, Kevin C.   +9 more
openaire   +2 more sources

Search for pyrenophorosis resistance allele Tsc2 in winter common wheat samples

Зерновое хозяйство России
Winter common wheat is one of the most important food crops in Russia and worldwide. It plays a vital role in ensuring food safety. This makes it important to develop varieties resistant to dangerous foliar diseases such as pyrenophorosis. One of the key
N. N. Vozhzhova, D. M. Marchenko
doaj   +1 more source

Ablation of TSC2 enhances insulin secretion by increasing the number of mitochondria through activation of mTORC1. [PDF]

PLoS ONE, 2011
AIM:We previously found that chronic tuberous sclerosis protein 2 (TSC2) deletion induces activation of mammalian target of rapamycin Complex 1 (mTORC1) and leads to hypertrophy of pancreatic beta cells from pancreatic beta cell-specific TSC2 knockout ...
Maki Koyanagi, Shun-ichiro Asahara, Tomokazu Matsuda, Naoko Hashimoto, Yutaka Shigeyama, Yuki Shibutani, Ayumi Kanno, Megumi Fuchita, Tomoko Mikami, Tetsutya Hosooka, Hiroshi Inoue, Michihiro Matsumoto, Masato Koike, Yasuo Uchiyama, Tetsuo Noda, Susumu Seino, Masato Kasuga, Yoshiaki Kido   +17 more
doaj   +1 more source

Abnormal KCC2 expression and function in a mouse model of epilepsy and tuberous sclerosis complex

Epilepsia, EarlyView.
Abstract Objective Drug‐resistant epilepsy is a common, severe manifestation of the genetic disorder tuberous sclerosis complex (TSC). Although significant mechanistic and therapeutic advances have been made in TSC, treatments for seizures remain largely ineffective.
Dongjun Guo, Lirong Han, Nicholas R. Rensing, Laura A. Jansen, Michael Wong   +4 more
wiley   +1 more source

Targeting Rb Mutant Cancers by Inactivating TSC2

Oncotarget, 2010
Retinoblastoma (Rb), a tumor suppressor gene, is inactivated in many types of cancer. However little is known about how the loss of Rb function can be targeted in cancer therapies. We have identified that inactivation of TSC2 in Rb mutant cancer cells will induce a synergistic cell death.
Jennifer S, Searle, Binghui, Li, Wei, Du
openaire   +2 more sources

Deep whole genome sequencing of epileptogenic brain lesions

Epilepsia, EarlyView.
Abstract Objective Malformations of cortical development and low‐grade epilepsy‐associated tumors often cause drug‐resistant lesional focal epilepsy (LFE) amenable to surgical treatment. Genetic testing of resected brain tissue can provide diagnostic and mechanistic information and may eventually support personalized treatment approaches.
Christian M. Boßelmann, Costin Leu, Lucas Hoffmann, Roland Coras, Katja Kobow, Hajo Hamer, Daniel Delev, Christian G. Bien, Thilo Kalbhenn, Tom Pieper, Till Hartlieb, Kerstin Becker, Lisa Ferguson, Robyn M. Busch, Peter Nürnberg, Imad Najm, Ingmar Blümcke, Dennis Lal   +17 more
wiley   +1 more source